Cogentis Therapeutics, Inc.
Developing first in class therapies for the treatment of dementia.
Developing first in class therapies for the treatment of dementia.
Cogentis Therapeutics, Inc. is an early stage biotechnology company with a mission to develop and commercialize an innovative disease-modifying therapeutic for dementias such as frontotemporal dementia (FTD) and Alzheimer’s disease (AD) to improve patients’ quality of life and reduce the burden of disease on their families, providers, and the overall healthcare system. Its immediate goal is to develop a peptide-based compound, CT-526, for FTD. Founded in 2015 and headquartered in the United States, this company is focused on the Biotechnology and Health Care sectors. Their slogan highlights their dedication to "Developing first in class therapies for the treatment of dementia." Cogentis has recently received Non Equity Assistance investment at 21 October 2020 from MassChallenge. This investment is a testament to the promise and potential of Cogentis Therapeutics' innovative approach in the biotechnology space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
21 Oct 2020 |
No recent news or press coverage available for Cogentis Therapeutics, Inc..
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
